Advertisement

Drugs & Aging

, Volume 8, Issue 2, pp 84–88 | Cite as

Use of Misoprostol in the Elderly

Is the Expense Justified?
  • Gerold Stucki
  • Magnus Johannesson
  • Matthew H. Liang
Leading Article

Summary

Misoprostol is a prostaglandin E1 analogue which reduces both gastric ulcerations and clinically important bleeding in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). Economic evaluations of prophylactic use of misoprostol with NSAIDs differ in their conclusions mainly because of different assumptions regarding the absolute risk reduction of symptomatic ulcers. Assuming a conservative estimate of the absolute risk reduction based on new effectiveness data, all studies would have concluded that misoprostol prophylaxis results in net costs in the general population of NSAID users. However, in the elderly with a clearly increased risk of gastrointestinal (GI) lesions and ulcer complications, and an increased hospitalisation rate, misoprostol may be cost saving. Also, in the elderly the gain in quality of life seems to offset the uncertain reduction in quality of life due to the adverse effects of misoprostol. However, the suggestion that misoprostol prophylaxis in the elderly is cost effective or cost saving needs to be confirmed in further studies.

Keywords

Economic Evaluation Gastric Ulcer Piroxicam Misoprostol Absolute Risk Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hawkey CJ. N of 1 trials in osteoarthritis. BMJ 1995; 310: 666–7PubMedCrossRefGoogle Scholar
  2. 2.
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787–96PubMedGoogle Scholar
  3. 3.
    Dieppe P, Cushnaghan J, Jasani MK, et al. I. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993; 32: 595–600PubMedCrossRefGoogle Scholar
  4. 4.
    Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647–55PubMedGoogle Scholar
  5. 5.
    Gabriel SE, Campion ME, O’Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37: 333–41PubMedCrossRefGoogle Scholar
  6. 6.
    De Pouvourville G. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy. Br J Rheumatol 1995; 34 Suppl. 1: 19–24PubMedGoogle Scholar
  7. 7.
    Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 1277–80PubMedCrossRefGoogle Scholar
  8. 8.
    Verdickt W, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 21: 85–91PubMedCrossRefGoogle Scholar
  9. 9.
    Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of the efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881–5PubMedCrossRefGoogle Scholar
  10. 10.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory agents. Ann Intern Med 1995; 123: 241–9PubMedGoogle Scholar
  11. 11.
    Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061–5PubMedCrossRefGoogle Scholar
  12. 12.
    Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639–46PubMedCrossRefGoogle Scholar
  13. 13.
    Jonsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992; 8: 234–44PubMedCrossRefGoogle Scholar
  14. 14.
    Edelson JT, Tosteson ANA. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal bleeding. JAMA 1990; 264: 41–7PubMedCrossRefGoogle Scholar
  15. 15.
    Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447–59PubMedCrossRefGoogle Scholar
  16. 16.
    Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? Arch Intern Med 1994; 154: 2020–5PubMedCrossRefGoogle Scholar
  17. 17.
    Gabriel SE. Has the cost-effectiveness of misoprostol been underestimated? [letter]. Arch Intern Med 1995; 155: 1448–9PubMedCrossRefGoogle Scholar
  18. 18.
    Fort JG, Hoffman HD. Cost-effectiveness and misoprostol [letter]. Arch Intern Med 1995; 155: 1448PubMedCrossRefGoogle Scholar
  19. 19.
    Stucki G, Johannesson M, Liang MH. Has the cost-effectiveness of misoprostol been underestimated? [letter]. Arch Intern Med 1995; 155: 1451–2CrossRefGoogle Scholar
  20. 20.
    International monetary fund: foreign exchange rates: 1970 to 1992. In: The world almanac and book of facts 1994. Mahwah (NJ): Funk & Wagnalls Corporation 1993: 114Google Scholar
  21. 21.
    Beck RJ, Pauker SG, Gottlieb JE, et al. I. A convenient approximation of life expectancy (the ‘deal’). II. Use in medical decision making. Am J Med 1982; 73: 889–97PubMedCrossRefGoogle Scholar
  22. 22.
    Soll AH, Isenberg JI. Duodenal ulcer diseases. In: Sleisenger MH, Fortran JS, editors. Gastrointestinal disease: pathophysiology, diagnosis and management. 3rd ed. Philadelphia (PA): WB Saunders Co, 1983Google Scholar
  23. 23.
    Walt RP. Misoprostol for the treatment of peptic ulcer and anti-inflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992; 327: 1575–80PubMedCrossRefGoogle Scholar
  24. 24.
    Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1987Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Gerold Stucki
    • 1
    • 3
  • Magnus Johannesson
    • 2
  • Matthew H. Liang
    • 3
  1. 1.Department of Rheumatology and Physical MedicineUniversity Hospital ZurichZürichSwitzerland
  2. 2.Centre for Health EconomicsStockholm School of EconomicsStockholmSweden
  3. 3.Departments of Medicine and Rheumatology/Immunology, and Robert B. Brigham Multipurpose Arthritis and Musculoskeletal Disease CenterBrigham and Women’s HospitalBostonUSA

Personalised recommendations